• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

In response to "Drug metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort".

作者信息

DeMichele Angela, Gimotty Phyllis, Botbyl Jeffrey, Aplenc Richard, Colligon Theresa, Foulkes Andrea S, Rebbeck Timothy R

出版信息

J Clin Oncol. 2007 Dec 10;25(35):5675-7. doi: 10.1200/JCO.2006.10.1485.

DOI:10.1200/JCO.2006.10.1485
PMID:18065748
Abstract
摘要

相似文献

1
In response to "Drug metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort".回应《药物代谢酶多态性预测淋巴结阳性乳腺癌队列的临床结局》
J Clin Oncol. 2007 Dec 10;25(35):5675-7. doi: 10.1200/JCO.2006.10.1485.
2
Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.药物代谢酶基因多态性可预测淋巴结阳性乳腺癌队列的临床结局。
J Clin Oncol. 2005 Aug 20;23(24):5552-9. doi: 10.1200/JCO.2005.06.208.
3
Cytochrome P450 polymorphisms and their relationship with premature ovarian failure in premenopausal women with breast cancer receiving doxorubicin and cyclophosphamide.
Breast J. 2011 Sep-Oct;17(5):536-8. doi: 10.1111/j.1524-4741.2011.01144.x. Epub 2011 Aug 9.
4
A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.一种用于预测系统辅助化疗后淋巴结阳性乳腺癌转移风险的38基因表达特征：PACS01临床试验的基因组子研究
Breast Cancer Res Treat. 2009 Aug;116(3):509-20. doi: 10.1007/s10549-008-0250-8. Epub 2008 Nov 20.
5
Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes?外源性物质代谢基因中的单核苷酸多态性是否决定乳腺癌易感性和治疗结果？
Cancer Invest. 2008 Oct;26(8):769-83. doi: 10.1080/07357900801953196.
6
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.绝经前淋巴结阳性乳腺癌患者辅助性环磷酰胺、甲氨蝶呤和氟尿嘧啶治疗：丹麦乳腺癌协作组（DBCG）77、82和89号试验中剂量与方案的间接比较
Acta Oncol. 2008;47(4):662-71. doi: 10.1080/02841860801989761.
7
The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).乳腺癌患者新辅助化疗的潜在风险——来自奥地利乳腺癌和结直肠癌研究组（ABCSG-07）前瞻性随机试验的结果
Breast Cancer Res Treat. 2008 Nov;112(2):309-16. doi: 10.1007/s10549-007-9844-9. Epub 2007 Dec 14.
8
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.氟尿嘧啶、表柔比星和环磷酰胺单药或序贯紫杉醇用于早期乳腺癌的随机3期试验。
J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. doi: 10.1093/jnci/djn151. Epub 2008 May 27.
9
Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.接受化疗的肝转移局限型乳腺癌患者的临床病程
Cancer J. 2008 Jan-Feb;14(1):62-8. doi: 10.1097/PPO.0b013e3181629a7b.
10
Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.口服尿嘧啶和替加氟与经典的环磷酰胺、甲氨蝶呤、氟尿嘧啶相比，用于淋巴结阴性、高危乳腺癌患者术后化疗：国家乳腺癌辅助治疗研究01试验
J Clin Oncol. 2009 Mar 20;27(9):1368-74. doi: 10.1200/JCO.2008.18.3939. Epub 2009 Feb 9.

引用本文的文献

1
Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study.基于候选基因法的欧洲女性儿童癌症幸存者队列中CYP450基因变异对性腺损伤的影响：泛癌生命研究结果
Cancers (Basel). 2021 Sep 13;13(18):4598. doi: 10.3390/cancers13184598.
2
Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors.药物代谢酶多态性与年轻乳腺癌幸存者化疗相关的卵巢功能衰竭。
J Obstet Gynaecol. 2021 Apr;41(3):447-452. doi: 10.1080/01443615.2020.1754369. Epub 2020 Jun 4.
3
Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients.
药物代谢酶编码基因多态性的广义多因素降维（GMDR）分析可能预测印度乳腺癌患者的治疗结果。
World J Surg. 2016 Jul;40(7):1600-10. doi: 10.1007/s00268-015-3263-6.
4
Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are associated with susceptibility and chemotherapy response in non-small-cell lung cancer patients.GSTM1、CYP1A1、CYP2E1 和 CYP2D6 基因多态性与非小细胞肺癌患者的易感性和化疗反应相关。
Lung. 2012 Feb;190(1):91-8. doi: 10.1007/s00408-011-9338-8. Epub 2011 Nov 23.
5
[Relationship between the genetic polymorphisms of phase I and II drug-metabolizing enzymes, as well as the outcome of chemotherapy in advanced non-small cell lung cancer].[Ⅰ期和Ⅱ期药物代谢酶的基因多态性与晚期非小细胞肺癌化疗结果的关系]
Zhongguo Fei Ai Za Zhi. 2011 Nov;14(11):858-64. doi: 10.3779/j.issn.1009-3419.2011.11.05.
6
Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.环磷酰胺代谢酶多态性与阳性淋巴结乳腺癌辅助化疗后生存结局的关系：一项回顾性队列研究。
Breast Cancer Res. 2010;12(3):R26. doi: 10.1186/bcr2570. Epub 2010 May 10.